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Abstract
Animal aging is characterized by progressive, degenerative changes in many organ sys-
tems. Because age-related degeneration is a major contributor to disability and death in
humans, treatments that delay age-related degeneration are desirable. However, no drugs
that delay normal human aging are currently available. To identify drugs that delay age-
related degeneration, we used the powerful Caenorhabdtitis elegansmodel system to
screen for FDA-approved drugs that can extend the adult lifespan of worms. Here we show
that captopril extended mean lifespan. Captopril is an angiotensin-converting enzyme
(ACE) inhibitor used to treat high blood pressure in humans. To explore the mechanism of
captopril, we analyzed the acn-1 gene that encodes the C. elegans homolog of ACE.
Reducing the activity of acn-1 extended the mean life span. Furthermore, reducing the
activity of acn-1 delayed age-related degenerative changes and increased stress resis-
tance, indicating that acn-1 influences aging. Captopril could not further extend the lifespan
of animals with reduced acn-1, suggesting they function in the same pathway; we propose
that captopril inhibits acn-1 to extend lifespan. To define the relationship with previously
characterized longevity pathways, we analyzed mutant animals. The lifespan extension
caused by reducing the activity of acn-1 was additive with caloric restriction and mitochon-
drial insufficiency, and did not require sir-2.1, hsf-1 or rict-1, suggesting that acn-1 functions
by a distinct mechanism. The interactions with the insulin/IGF-1 pathway were complex,
since the lifespan extensions caused by captopril and reducing acn-1 activity were additive
with daf-2 and age-1 but required daf-16. Captopril treatment and reducing acn-1 activity
caused similar effects in a wide range of genetic backgrounds, consistent with the model
that they act by the same mechanism. These results identify a new drug and a new gene
that can extend the lifespan of worms and suggest new therapeutic strategies for address-
ing age-related degenerative changes.
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Author Summary
Age-related degeneration is a fundamental feature of animal biology and an important
contributor to human disability and death. However, no medicines have been shown to
delay human aging. To identify drugs that delay age-related degeneration, we screened
FDA-approved compounds and discovered that the hypertension drug captopril signifi-
cantly extended C. elegans lifespan. In humans, captopril inhibits angiotensin converting
enzyme (ACE) to regulate blood pressure. The C. elegans homolog of ACE is encoded by
the acn-1 gene. We discovered that reducing the activity of acn-1 also caused a robust
extension of lifespan and delayed age-related changes in C. elegans. Captopril and acn-1
have a similar mechanism of action; both treatments displayed similar interactions with
previously characterized pathways, and combining treatment with captopril and reducing
the activity of acn-1 did not have an additive effect on life span extension. These results
identify a new drug and a new gene that influence aging in C. elegans. They may be rele-
vant to other animals such as humans because the pathway that includes ACE has been
conserved during evolution. These findings establish a foundation for possible therapeutic
interventions that can delay age-related degeneration.
Introduction
Animal aging is characterized by progressive, degenerative changes of tissue structure and
function. In humans, these changes have profound negative effects on health by causing mor-
bidity and mortality. An important goal of aging research is to identify interventions that can
delay age-related degeneration and promote an extended period of vitality or healthspan. How-
ever, no interventions have been demonstrated to delay human aging. By contrast, a growing
number of interventions have been demonstrated to delay age-related degeneration and extend
lifespan in model animals such as worms, flies and mice [1]. These interventions include die-
tary changes such as caloric restriction, genetic changes such as reducing the activity of the
insulin/insulin-like growth factor-1 (IGF-1) signaling pathway, and drugs such as rapamycin.
These studies indicate that pathways that influence aging have been conserved during animal
evolution [1]. Thus, model organisms are promising systems to identify and characterize inter-
ventions that promote healthy aging and may be beneficial in humans.
The terrestrial nematode Caenorhabditis elegans has emerged as an outstanding model
organism for studies of aging. The biology of these animals is well suited for studies of aging
because they have a rapid life cycle and a relatively short adult lifespan of about 15 days [2,3].
A wide variety of age-related degenerative changes have been documented, providing assays of
aging and suggesting C. elegans undergoes mechanisms of aging similar to larger animals
where progressive degenerative changes are well characterized [4]. Powerful experimental tech-
niques are well established, including forward and reverse genetic approaches and molecular
approaches facilitated by a fully sequenced genome [5,6]. C. elegans are well suited for pharma-
cological studies because they ingest compounds that are added to the culture medium. Molec-
ular genetic studies have identified and characterized several pathways that substantially
influence the rate of age-related degeneration. The insulin/IGF-1 pathway was first implicated
in aging biology in C. elegans and has now been shown to play a conserved role in other ani-
mals, including flies and mammals [1]. Mutations that reduce the activity of the daf-2 insulin
receptor or the age-1 phosphatidylinositol-3-OH (PI3) kinase substantially extend the adult
lifespan, indicating that insulin/IGF-1 pathway activity promotes a rapid lifespan [7,8]; these
mutant animals also display enhanced resistance to a variety of stresses such as UV light,
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oxidation, transition metals, and hypoxia [9–12]. A critical effector of the daf-2/age-1 pathway
is the forkhead transcription factor DAF-16, which is activated and localized to the nuclei by
low levels of daf-2 signaling [13,14]. The activity of daf-16 promotes an extended lifespan, and
daf-16 is necessary for the extension of lifespan caused by mutations of daf-2 and age-1 [8,15].
Caloric restriction extends the lifespan of a wide range of organisms, including C. elegans, indi-
cating that ad libitum feeding promotes a rapid lifespan. Mutations of genes that are necessary
for pharyngeal pumping and food ingestion, such as eat-2, cause a substantial lifespan exten-
sion [16]. Mutations in multiple genes that are necessary for mitochondrial function, such as
isp-1, cause a lifespan extension, indicating that wild-type levels of mitochondrial activity pro-
mote a rapid lifespan [17,18]. In addition to genetic approaches, C. elegans is emerging as a
valuable system for pharmacological approaches that can be used to identify and characterize
drugs that influence aging. Compounds that influence C. elegans aging have been identified by
screening approaches and by testing candidate drugs based on a known mechanism of action
[19–25].
To identify drugs that influence aging, we screened FDA-approved drugs for the ability to
extend the lifespan of C. elegans hermaphrodites. Here we report that captopril, an angiotensin
converting enzyme (ACE) inhibitor used to treat high blood pressure, extended mean lifespan.
ACE is a protease that functions in a signaling cascade that is initiated by low blood pressure;
in humans, ACE converts angiotensin I to angiotensin II, and angiotensin II binds the AT1
receptor, resulting in increased contractility of endothelial cells and thereby increasing blood
pressure [26,27]. ACE inhibitors such as captopril are used by a large number of people to con-
trol hypertension [27]. The ACE gene has been conserved from bacteria to mammals, indicat-
ing it had a primordial function before the evolution of a closed circulatory system that creates
blood pressure. The C. elegans homolog of ACE is encoded by the acn-1 gene; acn-1 is neces-
sary for larval molting but has not been previously implicated in adult longevity [28]. We
hypothesized that captopril inhibits acn-1 to extend lifespan, and here we present experimental
evidence that supports this model. First, inhibition of the acn-1 gene by RNA interference
extended lifespan and delayed age-related degenerative changes, indicating that acn-1 activity
influences aging and longevity. Second, captopril treatment and reducing the activity of acn-1
caused very similar effects in a wide range of genetic backgrounds, indicating that these inter-
ventions have a common mechanism. Third, the lifespan extensions caused by captopril treat-
ment and reducing the activity of acn-1 were not additive, indicating that these interventions
may affect the same pathway. These results identify captopril as a new, FDA-approved drug
that can extend the lifespan of C. elegans and acn-1 as a new gene that influences C. elegans
aging. The findings establish acn-1 as the target of captopril in worms, connecting a pharmaco-
logical intervention that extends lifespan to its direct molecular target. In mammals, ACE regu-
lates blood pressure, indicating there is a link between a system that controls aging in worms
and physiology in mammals.
Results
Captopril extended C. elegans lifespan
To identify drugs that influence aging, we selected 15 compounds that are Food and Drug
Administration (FDA)-approved for human use, have known effects on human physiology,
and represent different functional or structural classes (see Materials and Methods). Com-
pounds were added to NGM agar at three different concentrations, and the lifespan of C. ele-
gans hermaphrodites cultured at 20°C with E. coli OP50 as a food source was determined. We
previously described a similar screening approach that was used to identify the lifespan extend-
ing compounds ethosuximide and valproic acid [19,20]. Captopril, an ACE inhibitor, caused a
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significant extension of lifespan (Fig 1A and 1C). To identify the optimal concentration for life-
span extension, we performed a dose–response analysis. A concentration of 2.5mM captopril in
the medium caused the greatest lifespan extension, whereas concentrations of 1.9mM and
3.2mM caused smaller extensions (Fig 1B; Table 1, line 1–4). At the optimal concentration of
2.5mM, captopril treatment caused a significant 23% extension of mean adult lifespan and a sig-
nificant 18% extension of maximum adult lifespan (Fig 1C; Table 1, line 5–6). We define maxi-
mum adult lifespan as the average lifespan of the 10% of the population that are longest lived. To
determine the developmental stage when captopril functions to extend lifespan, we administered
the drug beginning at the L4 larval stage. The drug was effective with this time of administration
suggesting captopril functions in adults to delay age-related degeneration. To determine the tem-
perature dependence of captopril, we analyzed animals cultured at 15°C, 20°C and 25°C. Capto-
pril significantly extended the mean and maximum adult lifespan at all three temperatures,
indicating that the effect is not temperature dependent (Fig 1D; Table 1, line 7–10; S1A Fig).
These experiments were conducted with live E. coli as a food source, raising the possibility
that captopril may directly affect bacteria and indirectly affect worms. There are precedents for
Fig 1. Captopril extended the adult lifespan. (A) Structure of captopril. (B) Survival curves of wild-type (WT) hermaphrodites cultured at 20°C with no drug
or captopril (Cap) at concentrations of 1.9 mM, 2.54 mM and 3.18 mM in the NGMmedium. Hermaphrodites were exposed to captopril starting at the L4
stage (day 0) and monitored regularly until death. (C) Wild-type hermaphrodites were treated with no drug or 2.54 mM captopril at 20°C. These data
represent the analysis of 500 animals in 10 trials, whereas the data in panel B represent 58 animals in 2 trials. (D) WT hermaphrodites were cultured at 15°C.
See Table 1 for summary statistics, number of animals and number of independent experiments.
doi:10.1371/journal.pgen.1005866.g001
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such a mechanism, since antibiotics can extend C. elegans lifespan by reducing the pathogenic-
ity of bacteria [29–31], and the anti diabetic drug metformin was reported to extend C. elegans
lifespan by altering bacterial folate and methionine metabolism [32]. To determine if the effects
of captopril are mediated by an effect on live bacteria, we conducted the life span experiment
with bacteria killed by exposure to ultraviolet light. Captopril extended the lifespan of C. ele-
gans in these conditions, demonstrating that the mechanism of captopril-mediated lifespan
extension is not dependent on live E. coli (S1C Fig; Table 1, line 11–12).
A large number of age-related degenerative changes have been characterized in C. elegans,
including declines of physiological processes, such as body movement, pharyngeal pumping, and
egg-laying, and changes in morphology, such as loss of tissue integrity [4,33,34]. Treatment with
captopril caused a small delay in the age-related decline in pharyngeal pumping rate, although the
change was not statistically significant with the sample size analyzed (S2 Fig). Several genetic
manipulations that extend adult lifespan also affect reproduction. For example, caloric restriction
Table 1. Captopril extended adult lifespan.
Line Genotype1 Drug2 Mean3 lifespan ± SD (days) % Change Maximum3 lifespan ± SD (days) % Change N (n)4
1 WT None 15.9±5.0 24.9±1.0 48 (2)
2 WT Captopril (1.9 mM) 17.7±6.1ns +11 27.9±1.7* +11 35 (2)
3 WT Captopril (2.54 mM) 21.4±4.1*** +34 29.4±0.8*** +16 58 (2)
4 WT Captopril (3.18 mM) 18.4±5.2* +18 26.2±1.5ns +5 54 (2)
5 WT None 16.2±4.9 25.2±1.6 531 (10)
6 WT Captopril (2.54 mM) 19.9±6.1*** +23 29.8±1.5*** +18 500 (10)
7 WT 15°C None 20.3±4.1 27.4±1.7 67 (2)
8 WT 15°C Captopril (2.54 mM) 25.9±5.2*** +28 36.2±3.7*** +32 98 (2)
9 WT 25°C None 7.9±2.7 13.3±1.4 112 (3)
10 WT 25°C Captopril (2.54 mM) 10.0±3.8** +22 15.5±1.4** +16 77 (3)
11 WT (dead OP50) None 17.3±4.2 24.6±1.0 117 (3)
12 WT (dead OP50) Captopril (2.54 mM) 20.4±5.0*** +18 28.3±0.9*** +15 111 (3)
13 eat-2(ad1116) None 17.9±5.1 26.2±6.1 117 (3)
14 eat-2(ad1116) Captopril (2.54 mM) 20.4±1.1*** +14 30.7±1.4*** +17 122 (3)
15 isp-1(qm150) None 20.0±6.4 30.9±2.7 142 (3)
16 isp-1(qm150) Captopril (2.54 mM) 24.6±7.7*** +23 37.1±2.2*** +20 132 (3)
17 sir-2.1(ok434) None 17.0±3.7 23.42±1.2 188 (3)
18 sir-2.1(ok434) Captopril (2.54 mM) 19.8±4.9*** +17 29.7±3.6** +27 110 (3)
19 daf-16(mu86) None 12.6±3.5 18.4±1.7 200 (3)
20 daf-16(mu86) Captopril (2.54 mM) 11.3±2.7*** -10 16.4±1.7*** -11 202 (3)
21 daf-2(e1370) None 35.4±8.9 49.8±3.0 157 (4)
22 daf-2(e1370) Captopril (2.54 mM) 40.3±9.3*** +11 54.9±3.0** +9 184 (4)
1Genotype: Wild-type hermaphrodites or the indicated mutants were analyzed at 20°C, except those labeled 15°C or 25°C. Animals were cultured with live
E. coli OP50, except those labeled dead OP50, which were cultured with UV light killed bacteria.
2Drug: Animals were cultured on standard NGM (None) or on NGM containing the indicated concentration of captopril.
3Mean, Maximum, % Change: Maximum adult lifespan is the mean lifespan of the 10% of the population that had the longest lifespans. Comparisons are
to the paired no drug treatment control
*, P < 0.05
**, P < 0.005
***, P < 0.0001
n.s., not signiﬁcant, P>0.05.
4N(n): Total number of hermaphrodites analyzed, and the number of independent experiments.
doi:10.1371/journal.pgen.1005866.t001
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and defects in insulin/IGF-1 signaling reduce total progeny production and increase reproductive
span in self-fertile hermaphrodites [35]. To determine how captopril affects reproduction, we
monitored progeny production of self-fertile hermaphrodites daily. Captopril did not significantly
affect total brood size or reproductive span of self-fertile hermaphrodites (S3A and S3B Fig).
Reducing the activity of acn-1 extended lifespan
Captopril treatment in humans reduces blood pressure by inhibiting the activity of angiotensin
converting enzyme (ACE) [36]. Therefore, we hypothesized that captopril treatment in C. ele-
gans extends longevity by inhibiting the worm homolog of ACE. To investigate this hypothesis,
we analyzed the acn-1 gene because it encodes a predicted protein that is most similar to
human ACE [28]. To reduce the activity of acn-1, we used RNA interference (RNAi) [37];
worms were fed bacteria expressing dsRNA from the acn-1 gene, which is predicted to reduce
the levels of the acn-1 transcript. Wild-type animals cultured with acn-1 RNAi beginning at the
Fig 2. acn-1RNAi extended the adult lifespan. Survival curves of wild-type (WT) hermaphrodites (A, B) and rrf-3mutant hermaphrodites (C, D) cultured at
20°C with bacteria containing the control RNAi plasmid (L4440, blue) or the acn-1RNAi plasmid (red). Hermaphrodites were exposed to RNAi bacteria
starting at the embryonic stage (A, C, lifetime exposure) or the L4 stage (B, D, adult exposure). See Table 2 for summary statistics, number of animals and
number of independent experiments.
doi:10.1371/journal.pgen.1005866.g002
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embryonic stage displayed a significant extension of mean and maximum lifespan of 21% and
18%, respectively (Fig 2A, Table 2, line 1–2). These results indicate that acn-1 activity is neces-
sary to promote a rapid lifespan. To investigate the time of action of acn-1, we initiated the
exposure to acn-1 RNAi at the L4 larval stage. Exposure only during adulthood caused a similar
extension of mean and maximum lifespan of 22% and 20%, respectively, indicating that acn-1
functions in adults to promote a rapid lifespan (Fig 2B, Table 2, line 3–4).
Table 2. acn-1RNAi extended adult lifespan.
Line Genotype1 RNAi2 Mean3 lifespan ± SD (days) % Change Maximum3 lifespan ± SD (days) % Change N (n)4
1 WT Control 16.0±3.5 22.7±1.6 148 (3)
2 WT acn-1 19.3±4.4*** +21 26.8±1.0*** +18 154 (3)
3 WT Control (adult) 15.8±4.0 23.5±1.7 101 (2)
4 WT acn-1 (adult) 19.2±4.7*** +22 28.2±2.0*** +20 134 (2)
5 rrf-3(pk1426) Control 15.7± 4.0 22.7±1.2 503 (11)
6 rrf-3(pk1426) acn-1 20.9±4.2*** +33 28.1±1.2*** +24 620 (11)
7 rrf-3(pk1426) Control (adult) 14.9± 4.0 22.5± 1.4 189 (3)
8 rrf-3(pk1426) acn-1 (adult) 21.8±4.3*** +46 29.8± 1.7*** +33 203 (3)
9 rrf-3(pk1426) Control (25°C) 8.3± 1.2 10.4± 0.5 50 (1)
10 rrf-3(pk1426) acn-1 (25°C) 9.9±1.9*** +20 13.6± 0.5*** +31 50 (1)
11 eat-2(ad1116) Control 18.2±4.8 26.9±2.2 171 (3)
12 eat-2(ad1116) acn-1 20.3±5.1*** +12 29.4±1.9*** +10 231 (4)
13 isp-1(qm150) Control 23.3±6.2 33.2±1 199 (3)
14 isp-I(qm150) acn-1 26.4±7.4*** +14 37.3±2*** +13 151 (3)
15 sir-2.1(ok434) Control 14.8±2.8 19.8±1.0 203 (3)
16 sir-2.1(ok434) acn-1 17.5±3.1*** +16 23.0±1.3*** +18 214 (3)
17 rict-1(mg360) Control 12.1±2.6 16.7±0.8 113 (2)
18 rict-1(mg360) acn-1 14.9±3.0*** +23 20.9±11.3*** +25 145 (2)
19 hsf-1(sy441) Control 11.5±1.9 14.4±0.8 287 (7)
20 hsf-1(sy441) acn-1 13.0±2.1*** +12 16.1±0.8*** +11 413 (8)
21 daf-16(mu86) Control 11.8±2.3 16.1±1.4 341 (5)
22 daf-16(mu86) acn-1 11.4±2.5* -3 15.8±1.3ns -2 375 (5)
23 daf-2(e1370) Control 39.3±8.3 52.7±1.6 208 (3)
24 daf-2(e1370) acn-1 43.4±8.5*** +11 57.3±1.6*** +9 234 (3)
25 age-1(hx546) Control 20.7±6.4 30.3±1.5 65 (2)
26 age-1(hx546) acn-1 26.8±5.6*** +30 36.2±2.1*** +19 111 (2)
27 age-1(am88) Control 22.9±6.2 33.6±1.5 95 (2)
28 age-1(am88) acn-1 26.4±7.0*** +15 39.0±1.8*** +16 139 (2)
1Genotype: Wild-type hermaphrodites or the indicated mutants were analyzed.
2RNAi: Animals were cultured with bacteria containing the control RNAi plasmid (L4440) or the acn-1 RNAi plasmid. Culture temperature was 20°C,
except those labeled 25°C. Animals were cultured with RNAi bacteria starting at the embryonic stage (unlabeled) or the L4 stage (labeled adult).
3Mean, Maximum, % Change: Maximum adult lifespan is the mean lifespan of the 10% of the population that had the longest lifespans. Comparisons are
to the paired control RNAi
*, P < 0.05
**, P < 0.005
***, P < 0.0001
n.s., not signiﬁcant, P>0.05.
4N(n): Total number of hermaphrodites analyzed, and the number of independent experiments.
doi:10.1371/journal.pgen.1005866.t002
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Several mutations have been identified that increase the sensitivity of worms to feeding
RNAi, including mutation of rrf-3 [38]. Feeding acn-1 RNAi bacteria to rrf-3mutant animals
beginning at the embryonic stage caused a significant increase of mean and maximum lifespan
of 33% and 24%, respectively (Fig 2C, Table 2, line 5–6). Similarly, feeding acn-1 RNAi begin-
ning at the L4 stage caused a significant extension of mean and maximum lifespan of 46% and
33%, respectively (Fig 2D, Table 2, line 7–8). The extensions caused by acn-1 RNAi in the rrf-3
background were greater than the extensions in the wild-type background, indicating that rrf-3
mutant animals are indeed more susceptible to the effect of the RNAi treatment. Moreover,
acn-1 RNAi also caused a significant extension of mean and maximum lifespan of rrf-3mutant
animals at 25°C (S1B Fig, Table 2, line 9–10). To quantify how acn-1mRNA levels are affected
by feeding RNAi, we performed quantitative RT-PCR. acn-1 RNAi reduced mRNA levels
about 50% compared to control RNAi in rrf-3mutant animals (S4 Fig).
Reducing the activity of acn-1 delayed age-related degenerative changes
To characterize how acn-1 influences age-related degeneration, we monitored age-related
declines of major physiological processes. Wild-type C. elegans hermaphrodites display coordi-
nated, sinusoidal body movement as young adults, and the frequency and coordination of body
movement display age-related declines. To analyze body movement quantitatively, we counted
body bends on solid NGM using a dissecting microscope. Hermaphrodites cultured with acn-1
RNAi displayed a significantly higher rate of body movement beginning on day 4 of adulthood
and extending to day 26 of adulthood (Fig 3A). To illustrate this difference, we exploited the
fact that worms leave tracks in the bacterial lawn as they move. Five animals on day 15 of adult-
hood were transferred to fresh bacterial lawns, allowed to move for two hours, and the lawns
were photographed. Fig 3B shows that hermaphrodites treated with control RNAi left a small
number of tracks, and the tracks are suggestive of uncoordinated movement. By contrast, her-
maphrodites treated with acn-1 RNAi left abundant tracks that were suggestive of coordinated
sinusoidal movement.
We monitored the age-related decline in pharyngeal pumping rate quantitatively by direct
observation using a dissecting microscope. Hermaphrodites treated with acn-1 RNAi displayed
higher rates of pharyngeal pumping on days 12–20 of adulthood (Fig 3C). These results dem-
onstrate that acn-1 is necessary to promote the rapid, age-related decline of body movement
and pharyngeal pumping observed in wild-type animals.
To analyze the effect on reproduction, we monitored progeny production of self-fertile her-
maphrodites. Wild-type animals treated with acn-1 RNAi did not display significant changes
in total self fertile brood size or the daily production of progeny (S2C and S2D Fig). Captopril
treatment only slightly delayed age-related changes of pharyngeal pumping, whereas acn-1
RNAi significantly delayed age-related changes of pharyngeal pumping and body movement,
suggesting acn-1 RNAi may reduce the activity of acn-1 to a greater extent than captopril or
the drug may have toxic effects.
Reducing the activity of acn-1 increased stress resistance
Several C. elegansmutations that extend longevity also increase stress resistance [39,40]. To
investigate the function of acn-1 in stress resistance, we analyzed heat and oxidative stress.
Embryos were cultured at 20°C with control RNAi or acn-1 RNAi, and after 3 days animals
were transferred to stressful conditions and monitored for survival. When exposed to continu-
ous 34°C heat stress, control animals displayed a time dependent decrease in survival with a
mean lifespan of 14.0 hours; animals treated with acn-1 RNAi displayed a significant, 12%
extension of mean lifespan of 15.7 hours (Fig 4A, Table 3, line 1–2). When exposed to oxidative
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Fig 3. acn-1RNAi delayed age-related degenerative changes. rrf-3(pk1426)mutant hermaphrodites were
cultured at 20°C with bacteria containing the control RNAi plasmid (L4440, blue) or the acn-1RNAi plasmid
(red) starting at the embryonic stage. (A) Body movement was assessed by counting body bends with a
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stress caused by 40mM paraquat, control animals displayed a time dependent decrease in sur-
vival with a mean lifespan of 47.8 hours; animals treated with acn-1 RNAi displayed a signifi-
cant, 16% extension of mean lifespan of 55.4 hours (Fig 4B, Table 3, line 3–4). In addition, we
observed a similar result of extended survival in oxidative stress when wild-type animals were
treated with acn-1 RNAi (Fig 4C Table 3, line 5–6). To determine if the specific conditions or
oxidation generating chemical are important for the results, we analyzed oxidative stress in
dissecting microscope. (B) Images show bacterial lawns. Day 15 adults were cultured on fresh, smooth lawns
for two hours–lines are tracks caused by moving worms. Animals treated with acn-1RNAi generated more
tracks than control animals, and the tracks are suggestive of more coordinated sinusoidal movement
compared to control animals. (C) Pharyngeal pumping was assessed by counting pumps with a dissecting
microscope. n.s., P > 0.05; *, P < 0.05; **, P < 0.005; ***, P < 0.0001.
doi:10.1371/journal.pgen.1005866.g003
Fig 4. acn-1RNAi increased stress resistance.Hermaphrodites were cultured at 20°C with bacteria containing the control RNAi plasmid (L4440, blue) or
the acn-1 RNAi plasmid (red) starting at the embryonic stage. (A) rrf-3mutant animals were shifted to 34°C, a heat stress, and scored hourly for survival
starting at 6 hours. rrf-3mutant (B) or WT (C) animals were transferred to NGM dishes with 40 mM paraquat, an oxidative stress, and scored every 12 hours
for survival. (D) rrf-3mutant animals were transferred to liquid medium containing 240 uM juglone, another oxidative stress, and scored for survival after 9
hours. Bars indicate percent survival and standard deviation. See Table 3 for summary statistics, number of animals and number of independent
experiments. *, P < 0.05.
doi:10.1371/journal.pgen.1005866.g004
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liquid medium using the compound juglone to cause oxidative stress. After nine hours of
juglone exposure, animals treated with acn-1 RNAi displayed a significant, 56% increase in sur-
vival compared to control animals (Fig 4D Table 3, line 7–8). These results indicate that the
acn-1 gene is necessary to promote wild-type levels of sensitivity to multiple stresses including
heat and oxidation.
Captopril and acn-1 RNAi displayed similar interactions with mutations
that influence lifespan
To investigate the mechanism of action of captopril and acn-1 in lifespan extension, we analyzed
how captopril treatment and acn-1 RNAi affects animals with mutations that alter longevity.
Caloric restriction extends the lifespan of many organisms, indicating that ad libitum feeding
during laboratory culture reduces longevity. Mutations of the eat-2 gene impair pharyngeal
pumping, reduce food intake and cause a lifespan extension [16,41]. Captopril significantly
extended the mean and maximum lifespan of eat-2(ad1116)mutant animals by 14% and 17%,
respectively (Fig 5A; Table 1, line 13–14). Similarly, acn-1 RNAi significantly extended mean and
maximum lifespan by 12% and 10%, respectively (Fig 6A, Table 2, line 11–12). Thus, the lifespan
extension caused by caloric restriction was additive with captopril treatment and acn-1 RNAi.
Mutations of several genes that are important for mitochondrial function cause a lifespan
extension in C. elegans, indicating that normal mitochondrial function promotes a rapid life-
span. The isp-1 gene encodes a iron sulfur cluster containing protein that is important for the
function of complex III to catalyze electron transport from ubiquinol to cytochrome c, and isp-
1mutations extend lifespan [17,42]. Captopril treatment significantly extended the mean and
maximum lifespan of isp-1(qm150)mutant animals by 23% and 20%, respectively (Fig 5B;
Table 1, line 15–16). Similarly, acn-1 RNAi significantly extended mean and maximum lifespan
by 14% and 13%, respectively (Fig 6B, Table 2, line 13–14). Thus, the lifespan extension caused
by reducing mitochondrial function was additive with captopril treatment and acn-1 RNAi.
Overexpression of SIR2 (silent information regulator 2) is reported to extend the lifespan of
several organisms, although this effect is not always observed [43,44]. In C. elegans, sir-2.1 is
Table 3. acn-1RNAi caused resistance to oxidative and heat stress.
Line Genotype1 RNAi2 Stress3 Mean4 lifespan ± SD (hours) % Alive4 9hrs % Change4 N (n)5
1 rrf-3(pk1426) Control Heat Stress (34°C) 14.0±3.7 N/A 100 (3)
2 rrf-3(pk1426) acn-1 15.7±3.7* +12 112 (3)
3 rrf-3(pk1426)) Control Oxidative stress (paraquat) 47.8±1.5 N/A 86 (3)
4 rrf-3(pk1426) acn-1 55.4±1.7* +16 73 (3)
5 WT Control Oxidative stress (paraquat) 44.8± 1.3 N/A 32 (2)
6 WT acn-1 54.3±1.7* +21 52(2)
7 rrf-3(pk1426) Control Oxidative stress (juglone) N/A 29.5±6.8 134 (3)
8 rrf-3(pk1426) acn-1 45.9±2.8* +56 133 (3)
1Genotype: Wild-type hermaphrodites or rrf-3(pk1426) mutants were analyzed.
2RNAi: Animals were cultured with bacteria containing the control RNAi plasmid (L4440) or the acn-1 RNAi plasmid starting at the embryonic stage.
Culture temperature was 20°C, except during the heat stress.
3Stress: Animals were transferred to stressful conditions after 3 days, either 34°C heat stress, NGM dishes containing 40mM paraquat, or liquid medium
containing 240uM juglone.
4Mean, % Alive, % Change: Mean lifespan was calculated using Excel. Comparisons are to the paired control RNAi
*, P < 0.05.
5N(n): Total number of hermaphrodites analyzed, and the number of independent experiments.
doi:10.1371/journal.pgen.1005866.t003
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Fig 5. Captopril interactions with longevity pathways. Survival curves of mutant hermaphrodites cultured at 20°C with no drug or 2.54 mM captopril
(Cap). Hermaphrodites were exposed to captopril starting at the L4 stage (day 0) and monitored regularly until death. Genotypes were (A) eat-2(ad1116), (B)
isp-1(qm150), (C) sir-2.1(ok434), (D) daf-2(e1370) and (E) daf-16(mu86). See Table 1 for summary statistics, number of animals and number of independent
experiments.
doi:10.1371/journal.pgen.1005866.g005
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Fig 6. acn-1RNAi interactions with longevity pathways. Survival curves of mutant hermaphrodites cultured at 20°C with bacteria containing the control
RNAi plasmid (L4440, blue) or the acn-1RNAi plasmid (red). Hermaphrodites were exposed to RNAi bacteria starting at the embryonic stage and monitored
regularly until death. Genotypes were (A) eat-2 (ad1116), (B) isp-1 (qm150), (C) sir-2.1 (ok434), (D) daf-2 (e1370), (E) daf-16 (mu86), (F) age-1 (hx546), (G)
rict-1 (mg360) and (H) hsf-1 (sy441). See Table 2 for summary statistics, number of animals and number of independent experiments.
doi:10.1371/journal.pgen.1005866.g006
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predicted to encode a nicotinamide adenine dinucleotide (NAD) dependent deacetylase that
can extend the lifespan of C. elegans when overexpressed. We examined the null mutation sir-
2.1(ok434) [45]. Captopril treatment significantly extended the mean and maximum lifespan of
sir-2.1(ok434)mutant animals by 17% and 27%, respectively (Fig 5C; Table 1, line 17–18). Sim-
ilarly, acn-1 RNAi significantly extended the mean and maximum lifespan of sir-2.1mutants
by 16% and 18%, respectively (Fig 6C, Table 2, line 15–16). Thus, sir-2.1 activity was not neces-
sary for the lifespan extension activity of captopril or acn-1 RNAi.
The target of rapamycin (TOR) signaling network plays an important role in nutrient
homeostasis and influences adult lifespan [46]. Loss-of-function mutations in rict-1 affect TOR
signaling and cause a shorter lifespan. acn-1 RNAi significantly extended the mean and maxi-
mum lifespan of rict-1mutants by 23% and 25%, respectively (Fig 6G, Table 2, line 17–18). hsf-
1 encodes a transcription factor that is important for stress response; overexpression of hsf-1
extends lifespan and delays age-related protein miss folding [47], whereas reducing the activity
of hsf-1 causes a shorter lifespan and proteotoxicity [31,48,49]. acn-1 RNAi significantly
extended the mean and maximum lifespan of hsf-1(lf)mutants by 12% and 11%, respectively
(Fig 6H, Table 2, line 19–20). Thus, the activities of rict-1 and hsf-1 were not necessary for the
lifespan extension caused by acn-1 RNAi.
Mutations in the insulin/insulin-like growth factor (IGF) signaling pathway influence C. ele-
gans lifespan [7,8,50–53]. Mutations that partially reduce the activity of daf-2, which encodes a
protein homologous to the vertebrate insulin/IGF-1 receptor, or age-1, which encodes a protein
homologous to the vertebrate PI3 kinase, extend lifespan. This signaling pathway controls the
activity of a FOXO transcription factor encoded by daf-16, and daf-16 activity is necessary for
the lifespan extension caused by mutations in upstream signaling genes [13,14]. Thus, daf-2
and age-1 activity promote a rapid lifespan and inhibit longevity, whereas daf-16 activity pro-
motes longevity. Captopril treatment significantly extended the mean and maximum lifespan
of daf-2(e1370) partial loss-of-function mutant animals by 11% and 9%, respectively (Fig 5D;
Table 1, line 21–22). Similarly, acn-1 RNAi significantly extended mean and maximum lifespan
by 11% and 9%, respectively (Fig 6D, Table 2, line 23–24). In combination with an age-1
(hx546) partial loss-of-function mutation that causes an extended lifespan, acn-1 RNAi signifi-
cantly extended mean and maximum lifespan by 30% and 19%, respectively (Fig 6F, Table 2,
line 25–26). A similar result was obtained by analyzing age-1(am88)mutant animals (Table 2,
line 27–28, S5 Fig) [54]. Thus, the lifespan extension caused by reducing daf-2 activity was
additive with captopril treatment and acn-1 RNAi, and the lifespan extension caused by reduc-
ing age-1 activity was additive with acn-1 RNAi.
By contrast, captopril treatment did not extend the lifespan of daf-16 (mu86) loss-of-func-
tion mutant animals, but rather significantly shortened the mean and maximum lifespan by
10% and 11%, respectively (Fig 5E; Table 1, line 19–20). Similarly, acn-1 RNAi slightly short-
ened the mean and maximum lifespan by 3% and 2%, respectively (Fig 6E, Table 2, line 21–
22). These findings indicate that the lifespan extension activity of captopril and acn-1 RNAi
require daf-16 activity; however, the reduction of lifespan raises the possibility that the combi-
nation of captopril treatment or acn-1 RNAi and the daf-16mutation causes toxicity.
To investigate the possibility that acn-1 functions upstream of daf-16, we analyzed addi-
tional phenotypes associated with the insulin/IGF-1 pathway. Upstream signaling proteins
such as DAF-2 control the activity of DAF-16; specifically, daf-2(lf)mutations that cause a life-
span extension also cause DAF-16 protein to localize to the nucleus, where DAF-16 controls
the activity of target genes [55]. To examine the nuclear localization of DAF-16, we used trans-
genic worms containing a DAF-16::GFP reporter construct [56]. Animals treated with capto-
pril or acn-1 RNAi did not display a substantial nuclear localization of DAF-16::GFP
compared to control animals (S6C Fig, S1 Table). Thus, acn-1 RNAi did not cause the same
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effect as a daf-2(lf)mutation, and acn-1 is not necessary to inhibit nuclear localization of DAF-
16. It has been proposed that daf-16 is regulated by additional mechanisms that do not involve
changes in subcellular localization, such as transcript levels [57], EAK-7 [58], and phosphoryla-
tion [59,60]. Our results do not exclude the possibility that captopril or acn-1 RNAi regulate
daf-16 in a manner that does not change nuclear localization.
daf-2(lf)mutations cause a dauer constitutive (Daf-c) phenotype, indicating that daf-2 is
necessary to inhibit dauer development. To analyze the role of acn-1 in dauer formation, we
cultured worms with acn-1 RNAi bacteria at 20°C, shifted embryos to 27°C to stimulate dauer
formation, and scored dauer larvae after 72 hours. acn-1 RNAi did not increase the frequency
of dauer formation compared to control RNAi in wild-type animals or rrf-3mutant animals
(S6A Fig). To increase the sensitivity of the assay, we analyzed the function of acn-1 in daf-2(lf)
mutants that display a partially penetrant, temperature sensitive Daf-c phenotype [61]. acn-1
RNAi was not different from control RNAi in this assay (S6B Fig). Thus, acn-1 RNAi did not
cause the same effect on dauer formation as a daf-2(lf)mutation, and acn-1 is not necessary to
inhibit formation of dauer larvae.
The lifespan extensions caused by captopril and acn-1 RNAi were not
additive
We hypothesized that captopril inhibits acn-1 to extend lifespan. This hypothesis predicts that
the effects of captopril and acn-1 RNAi will not be additive, because our dose-response analysis
indicates that we have identified the optimal dose of captopril for lifespan extension. To test
this prediction, we combined treatment with captopril and acn-1 RNAi. Captopril treatment
alone caused a 20% extension of mean lifespan to 18.7 days, whereas acn-1 RNAi alone caused
a 38% extension of mean lifespan to 21.5 days (Fig 7A, Table 4, line 1–3). Combining captopril
treatment and acn-1 RNAi resulted in a 18.9 day lifespan that was not significantly different
from captopril treatment alone and significantly shorter than acn-1 RNAi treatment alone.
Thus, captopril and acn-1 RNAi did not have an additive effect on lifespan extension, consis-
tent with the model that both effects are mediated by a similar mechanism.
Discussion
Identification of captopril as a new drug that extends C. elegans
longevity
The identification of compounds that can delay age-related degeneration and extend lifespan is
an important goal of aging research, because age-related decline is a major cause of disability
and death in humans, and so far no compounds have been demonstrated to delay human
aging. We reasoned that FDA-approved drugs used to treat human diseases might also influ-
ence aging and lifespan. To identify such drugs, we screened examples of different structural
and functional drug classes. We previously described the identification of anticonvulsant drugs
such as ethosuximide and the neuroactive drug valproic acid [19,20]. Here we identified the
blood pressure medicine captopril as a way to extend C. elegans lifespan. The effect of captopril
was dose dependent; at an optimal dose, captopril significantly extended mean lifespan 22–
28% and maximum lifespan 18–32%. Captopril extended lifespan at a variety of temperatures
and in a variety of mutant backgrounds, indicating that the effect is robust in the face of envi-
ronmental and genetic variation. Captopril functioned in adult animals to extend lifespan, sug-
gesting that it affects the rate of age-related decline rather than developmental processes.
The first of what is now a large class of ACE inhibitors, captopril is an oligopeptide deriva-
tive developed in 1975 based on a peptide found in pit viper venom [62]. ACE inhibitors
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Fig 7. Captopril extends lifespan by reducing the activity of acn-1. (A) Survival curves of rrf-3(pk1426)mutant hermaphrodites cultured at 20°C with
bacteria containing the control RNAi plasmid (L4440) or the acn-1RNAi plasmid. Hermaphrodites were exposed to RNAi bacteria starting at the embryonic
stage. Hermaphrodites were cultured with no drug or 2.54 mM captopril (Cap) starting at the L4 stage (day 0). See Table 4 for summary statistics, number of
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modulate the renin-angiotensin-aldosterone system, a mechanism by which the body adapts to
hypotension [63]. In response to a decline in blood pressure, the kidney releases renin, which
cleaves angiotensinogen to angiotensin I. ACE converts angiotensin I to angiotensin II, and
angiotensin II acts through a transmembrane receptor to stimulate aldosterone secretion and
promote vasoconstriction to increase blood pressure. By blocking ACE and preventing the con-
version of angiotensin I to angiotensin II, captopril lowers blood pressure.
Two strategies have been used to identify compounds that can extend C. elegans lifespan:
screening chemical libraries and testing candidate compounds based on the hypothesis that the
target of the drug may influence aging and longevity [64]. Compounds that have been tested
included FDA-approved drugs, libraries of chemically defined molecules, and extracts of plants
that contain a mixture of chemicals. Library screening resulted in the identification of antide-
pressant drugs [21,25]. Candidate compounds that have been reported to extend worm lifespan
include resveratrol [65], trehalose [24], lithium [66] and garlic constituent [67]. Extracts of
blueberries and ginkgo have been reported to extend worm lifespan [68,69]. ACE inhibitors
such as captopril have not been previously reported to extend lifespan in worms, so our find-
ings identify a new chemical entity that influences aging in C. elegans.
Captopril inhibits acn-1 to delay aging in C. elegans
It is well established that ACE is the target that mediates the effect of captopril on blood pres-
sure in humans [62]. ACE genes have been highly conserved during evolution, and acn-1
encodes the C. elegans homolog of ACE [28]. A major issue in aging pharmacology is the
animals and number of independent experiments. (B) A model illustrating the relationship between captopril and acn-1 in C. elegans. Bars indicate a negative
effect, and arrows indicate a positive effect. (C) In humans, captopril inhibits angiotensin-converting enzyme (ACE), which catalyzes the cleavage of
angiotensin I to angiotensin II. Angiotensin II promotes high blood pressure and has other effects on physiology [26,27].
doi:10.1371/journal.pgen.1005866.g007
Table 4. Captopril and acn-1RNAi were not additive.

















18.7±5.0** +20 27.2±0.9*** +18 98 (3)
3 rrf-3
(pk1426)





18.9±5.6 +1/-12 27.5±1.0 +1/-4 130
(3)
1Genotype: rrf-3(pk1426) hermaphrodites were analyzed.
2RNAi: Animals were cultured at 20°C with bacteria containing the control RNAi plasmid (L4440) or the acn-1 RNAi plasmid starting at the embryonic
stage.
3Drug: Animals were cultured on standard NGM (None) or with NGM containing 2.54 mM captopril starting at the L4 stage.
4Mean, Maximum, % Change: Maximum adult lifespan is the mean lifespan of the 10% of the population that had the longest lifespans. Lines 2 and 3 are
compared to line 1, and line 4 is compared to line 2/line 3. There was no signiﬁcant difference between lines 4 and 2, whereas line 4 was signiﬁcantly
shorter then line 3 (P < 0.05 or P < 0.0001).
*, P < 0.05
**, P < 0.005
***, P < 0.0001; n.s., not signiﬁcant, P>0.05.
5N(n): Total number of hermaphrodites analyzed, and the number of independent experiments.
doi:10.1371/journal.pgen.1005866.t004
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identification of the direct target of the drug, and in most cases the targets of drugs that extend
C. elegans lifespan remain unknown. We hypothesized that captopril inhibits ACN-1 to extend
longevity. This hypothesis makes three important predictions that were verified experimen-
tally. First, it predicts that reducing the activity of acn-1 using genetic techniques can extend
longevity. We showed that targeting acn-1 by RNAi increased mean lifespan 20–46% and max-
imum lifespan 18–33%. Second, it predicts that reducing the activity of acn-1 and treatment
with captopril will cause similar effects in a variety of genetic backgrounds. Indeed, captopril
treatment and reducing acn-1 activity gave very similar results in five genetic backgrounds
(eat-2, isp-1, sir-2.1, daf-16 and daf-2) and at two temperatures. In addition, both treatments
function in adults to extend longevity. Third, it predicts that the lifespan extension caused by
captopril treatment and reducing acn-1 activity will not be additive. This prediction was also
verified. While these results are consistent with captopril inhibition of ACN-1, they do not
demonstrate that the drug directly binds ACN-1 protein or inhibits a biochemical activity of
ACN-1. The biochemical activity of ACN-1 has not been established, and ACN-1 may not
have protease activity because critical residues in the predicted active site have not been con-
served during evolution [28]. Further studies are necessary to establish an assay for the bio-
chemical activity of ACN-1 and directly test the effect of captopril.
The expression and function of acn-1 were analyzed by Brooks et al. [28] using a reporter
gene encoding ACN-1::GFP and acn-1 RNAi, respectively. acn-1 is expressed in embryonic
and larval hypodermis, in the vulva during organogenesis and in the ray papillae of the male
tail. RNAi delivered by injection in the gonad caused larvae to arrest at the L2 stage and display
evidence of molting defects. RNAi delivered by feeding to L1/L2 larvae caused a cuticle defec-
tive phenotype in L3/L4 larvae and adults. The failure to shed cuticle led to secondary defects
such as vulva defects and constipation. These results indicate acn-1 is necessary for larval molt-
ing, mail tail development and formation of adult alae. Frand et al. [70] identified acn-1 in a
genome-wide feeding RNAi screen for molting defects. An ACN-1::GFP transgene was
expressed in the hypodermis, including the major body syncytium, hyp7, and hypodermal cells
in the head and tail, the lateral seam cells, and the excretory gland cell. Neither of these studies
describe aging phenotypes, so our results establish a new phenotype for acn-1 and a novel link
between acn-1 and aging. The previously reported molting defects caused by acn-1 RNAi are
partially penetrant [28,70]; we did not observe a significant penetrance of molting defects,
which may indicate less extreme gene disruption in our studies resulting from differences
between the feeding RNAi constructs or the conditions of RNAi delivery.
To elucidate the role of captopril and acn-1 in aging, we analyzed interactions with estab-
lished pathways that influence longevity. Many mutations used in these experiments are not
null alleles, and therefore the observation that the effects are additive does not exclude the pos-
sibility that two interventions act in the same pathway. Captopril treatment or reducing the
activity of acn-1 was additive with the lifespan extensions caused by an eat-2mutation that
causes caloric restriction. Furthermore, these treatments did not reduce self-fertile brood size
and reproductive span like caloric restriction, suggesting that captopril and acn-1 do not act by
causing caloric restriction. Captopril treatment or reducing the activity of acn-1 was additive
with the lifespan extensions caused an isp-1mutation that reduces mitochondrial activity, sug-
gesting these treatments do not reduce mitochondrial function. The lifespan extension caused
by reducing the activity of acn-1 was not abrogated by loss-of-function mutations of sir-2.1,
hsf-1 or rict-1, suggesting that acn-1 does not act by regulating these genes. Captopril treatment
and reducing the activity of acn-1 displayed complex interactions with the insulin/IGF-1 path-
way. These treatments were additive with the lifespan extensions caused by loss-of-function
mutations of daf-2 and age-1. However, the lifespan extensions caused by both treatments were
abrogated by a daf-16mutation. To further analyze the relationship with daf-16, we
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demonstrated that reducing the activity of acn-1 did not cause dauer formation and did not
promote nuclear localization of DAF-16, which are typical of reducing insulin/IGF-1 signaling
upstream of daf-16. Thus, acn-1 does not appear to act upstream and regulate the nuclear local-
ization activity of daf-16. It is possible that daf-16 is necessary because it functions in parallel to
acn-1 or that toxicity develops in the absence of both daf-16 and acn-1. Overall, acn-1 defines a
new gene that influences longevity, and interactions with known longevity pathways suggest
that it functions by a mechanism that is distinct from those that have been characterized
previously.
The ACE pathway may have a conserved function influencing aging in
mammals
The ACE inhibitor enalapril and the angiotensin II receptor antagonist losartan have been
reported to extend the life span of mice and rats [71–78]. Furthermore, these drugs delay the
age-related degeneration of tissue structure and function in the kidney, cardiovascular system,
liver and brain. Similarly, Santos et al., [79] showed that enalapril increased life span in rats.
These interesting results indicate that the renin-angiotensin-aldosterone system promotes age-
related degeneration, and blocking this system can extend longevity in rodents. The mecha-
nism of these drugs in life span extension is not well defined–the affects are not well correlated
with changes in blood pressure but may reflect preservation of mitochondrial number and
function. Genetic studies reported by Benigni et al., [80] provide important support for these
pharmacology studies, since disruption of the angiotensin II type I receptor (AT1) promotes
longevity in mice. These results may be relevant to humans, since polymorphisms in the angio-
tensin II type I receptor gene are associated with extreme human longevity [81]. Overall, these
studies suggest that the rennin-angiotensin-aldosterone system controls longevity in mammals.
Thus, our discoveries in worms are likely to be relevant to mammalian biology. An important
issue that has not been established by studies of mammals is the mechanism of action of this
pathway in influencing aging and longevity. The results presented here provide new insights
into the mechanism of action of captopril in lifespan extension and establish the powerful C.
elegans system to investigate critical questions about the conserved activity of the pathway.
Materials and Methods
General methods and strains
C. elegans were cultured on 6 cm Petri dishes containing NGM agar and a lawn of Escherichia
coli strain OP50 at 20°C unless stated otherwise [2]. The wild-type (WT) strain was N2 Bristol.
daf-2(e1370P1465S) is a partial loss-of-function mutation that affects the kinase domain of the
DAF-2 receptor tyrosine kinase [50]. age-1(hx546P806S) and age-1(am88E725K) are partial
loss-of-function mutations that affect the AGE-1 PI3 kinase [53,54,82]. daf-16(mu86) is a
strong loss-of-function mutation caused by a deletion in the DAF-16 forkhead transcription
factor [13,14]; eat-2(ad1116) is a change in a splicing site predicted to decrease the level of
mRNA of the EAT-2 non-alpha nicotinic acetylcholine receptor [41]; isp-1(qm150P225S) is a
loss-of-function mutation that affects an iron sulfur protein of mitochondrial complex III [42];
sir-2.1(ok434) is a deletion that causes a loss-of-function of the SIR-2.1 NAD dependent pro-
tein deacetylase [45]. rict-1(mg360G1067E) is a partial loss-of-function mutation of RICT-1, a
component of the target of rapamycin complex 2 (TORC2) that encodes an ortholog of mam-
malian Rictor [83]. hsf-1(sy441W585stop) is a strong loss-of-function mutation of the HSF-1
transcription factor [84]. DAF-16 nuclear localization was analyzed using strain GR1352
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containing the integrated array xrIs87 [DAF-16alpha::GFP::DAF-16B + rol-6(su1006)] [85].
The rrf-3(pk1426)mutation was used for RNAi feeding experiments [38].
Screening for drugs that extend C. elegans lifespan
Fifteen FDA-approved drugs were screened for extension of C. elegans lifespan using methods
described by Evason et al., [19] (atropine, yohimbine hydrochloride, captopril, nicotinic acid,
phenformin, haloperidol, acetazolam, adenosine, cimetidine, lidocaine, procainamide hydro-
chloride, caramazepine, 5’-5’-diphenylhydation Sodium, caffeine and imipramine). For each
drug, we analyzed about 50 hermaphrodites cultured with three concentrations in the NGM
medium (X, 10-100X, 1000X). The lowest dose (X) was approximately equivalent to the effec-
tive dose in humans [63]. Captopril was obtained from Sigma Aldrich (St. Louis, MO, USA),
and a 30 mg/ml stock solution was prepared by dissolving the compound in water. Concen-
trated captopril was diluted to the desired final concentration in liquid NGM that had been
autoclaved and cooled to 55°C, and 7–8 ml of medium was dispensed into 6 cm Petri dishes.
Petri dishes were allowed to dry 1–2 days at room temperature and then seeded with E. coli
OP50. Lifespan experiments using dishes containing drugs were always conducted in parallel
with control dishes containing no drug in the same incubator to control for day-to-day varia-
tions in temperature and humidity.
Measurement of lifespan and age-related changes in physiological
process
Studies of lifespan were begun on day zero by placing approximately 30–40 L4 hermaphrodites
on a Petri dish. Each hermaphrodite was transferred to a fresh Petri dish daily during the
reproductive period (approximately the first seven days) to eliminate self-progeny and every
2–3 days thereafter. Each hermaphrodite was examined every day using a dissecting micro-
scope for survival, determined by spontaneous movement or movement in response to prod-
ding with a pick. Dead worms that displayed matricidal hatching, vulval extrusion or
desiccation due to crawling off the agar were excluded from the data analysis. Average mean
lifespan was calculated as the number of days from the L4 stage to the last day a worm was
observed to be alive. To conduct experiments with dead bacteria, we seeded dishes with live E.
coli OP50, cultured for 24 hours, and exposed the bacteria to ultraviolet light by placing dishes
in a UV Stratalinker 2400 for 15 minutes. Death was confirmed by inoculating LB medium
with treated bacteria and observing no growth.
To analyze progeny production, one L4 hermaphrodite was placed on a Petri dish (day
one), transferred to a fresh dish daily until at least 4 days without progeny production, and
progeny were counted after two days. Pharyngeal pumping and body movement were deter-
mined as described previously [33]. Briefly, we observed pharyngeal pumping using a dissect-
ing microscope for a 10 seconds interval. Body movement was assayed by observation using a
dissecting microscope for 20 seconds. Petri-dishes were tapped to stimulate animals to move
before scoring.
RNA interference
RNAi interference was performed by feeding bacteria that express dsRNA as described by
Kammath et al., [86]. Briefly, E. coliHT115 bacteria with the control plasmid (L4440) or a plas-
mid encoding acn-1 were obtained from the Ahringer library [37], and the identity of the clone
was confirmed by DNA sequencing. The daf-2 RNAi bacterial strain was provided by M. Crow-
der. RNAi bacteria were streaked on LB dishes containing 50μg/ml ampicillin and 12.5 μg/ml
tetracycline. Control and acn-1 RNAi cultures were grown for 6 hours in LB medium
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containing 50μg/ml ampicillin. Escherichia Coli expressing double-stranded acn-1 RNA did
not form thick lawns on RNAi NGM agar dishes containing isopropyl β-d-1-thiogalactopyra-
noside (1 mM) and 50μg/ml carbenicillin, indicating double stranded acn-1 RNAmight inhibit
bacterial proliferation. To address this issue, we prepared 3X-concentrated liquid bacterial cul-
ture from both control and acn-1 RNAi bacteria, spread this on NGM RNAi dishes, and
allowed dishes to incubate overnight. L4 stage larvae were transferred to RNAi dishes and cul-
tured for one day, adults were transferred to a fresh RNAi dish and cultured for one day and
then removed. Larva that developed on these plates were analyzed.
Dauer formation and DAF-16::GFP nuclear localization
Dauer formation was assayed as described by Kimura et al., [50]. Briefly, we collected eggs
from wild-type or rrf-3(pk1426) hermaphrodites cultured at 20°, transferred the eggs to 27°C
with ample food, cultured for 72 hr, and examined hatched animals. Animals were classified as
non-dauer (including adults and non-dauer larvae) or dauer on the basis of morphological cri-
teria [61]. To analyze dauer formation of daf-2(e1370)mutant animals, we transferred eggs to
15°C, 17.5°C, 20°C, 22.5°C, or 25°C. For dauer formation experiments, we performed acn-1
RNAi using the feeding protocol described by Kammath et al., [86]. Briefly, L4 stage hermaph-
rodites were transferred to dishes with control (L4440) or acn-1 RNAi bacteria at 20°C, and
embryos were transferred to fresh dishes with RNAi bacteria at the appropriate temperature
and cultured for 3 or 4 days.
To analyze DAF-16::GFP localization, we used the strain GR1352 [85]. L4 stage animals
were transferred to dishes seeded with control (L4440) and acn-1 RNAi bacteria. Progeny were
analyzed at the one day old adult stage using an Olympus SZX12 dissecting microscope
(Tokyo, Japan) equipped for fluorescence microscopy. To reduce bias, the scoring was done by
an observer blind to the RNAi treatment status. We analyzed each worm as having (1) GFP dif-
fusely localized in the cytosol, (2) GFP localized in nuclei displaying intensely fluorescing
puncta throughout the entire body from head to tail or (3) intermediate nuclear localization of
GFP, defined as puncta observed in at least one or more nuclei but not in most or all nuclei. To
perform the data analysis, we combined the nuclear and intermediate nuclear categories.
Heat and oxidative stress assays
Thermotolerance assays were performed as described by McColl et al., [87]. Briefly, L4 stage
hermaphrodites were cultured at 20°C on control (L4440) and acn-1 RNAi dishes for 3 days.
To perform the heat stress assay, we transferred adults to 34°C and scored the percentage of
dead and live animals starting at 6 hours and continuing every hour until all animals died. Ani-
mals were scored as dead if they did not respond to a mechanical stimulus. To perform oxida-
tive stress assays, we transferred day 3 adult hermaphrodites to NGM dishes containing 40
mM paraquat and scored for survival every 12 hours. For the heat stress and paraquat stress
assays, animals that displayed matricidal hatching or vulval extrusion were not included in the
data analysis. To perform oxidative stress assays with juglone, we transferred day 3 adult her-
maphrodites to 2 ml of liquid M9 medium containing 240 uM juglone in an 18 well dish.
Worms were scored for survival after 9 hours. Paraquat and juglone were obtained from Sigma
Aldrich (St. Louis, MO, USA).
Quantitative real-time PCR (RT–PCR)
To quantify mRNA levels, we cultured rrf-3 adult worms on control and acn-1 RNAi dishes for
3–4 hours to obtain synchronized eggs, removed adult worms, and continued culture until the
eggs developed into two day old adult worms. These adults were washed and collected for RNA
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isolation. RNA analysis was performed as previously described with modifications [88]. Briefly,
RNA was isolated using Trizol (Invitrogen) and treated with DNAse 1 enzyme. cDNA was syn-
thesized by using High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Quan-
titative, realtime PCR was performed using an Applied Biosystems Step One Plus Real-Time
PCR system and iTaq Universal SYBR Green Supermix (BioRad Laboratories, Hercules, CA).
mRNA fold change was determined by comparing acn-1mRNA levels with mRNA levels of
the reference gene rps-23. Forward and reverse amplification primers were: rps-23 50- aaggctca-
cattggaactcg and 50- aggctgcttagcttcgacac; acn-1 50- gtactacgagccactcatcaac and 50-
gaatctcctcgacagtgaatg.
Statistical analysis
All data were analyzed using the two-tailed student t-test for samples with unequal variances
by using Excel and http://studentsttest.com. P values less than 0.05 were considered statistically
significant. To determine if the choice of a statistical test affected the conclusions, we used the
log rank (Mantel-Cox) method to analyze a subset of the lifespan experiments. Both tests pro-
duced similar P values.
Supporting Information
S1 Fig. Captopril and acn-1 RNAi extended adult lifespan at 25°C, and captopril extended
adult lifespan when cultured with dead bacteria. (A) Survival curves of wild-type (WT) her-
maphrodites cultured at 25°C with no drug or 2.54 mM captopril (Cap) in the NGMmedium.
Hermaphrodites were exposed to captopril starting at the L4 stage (day 0) and monitored regu-
larly until death. See Table 1 for summary statistics, number of animals and number of inde-
pendent experiments. (B) Survival curves of rrf-3mutant hermaphrodites cultured at 25°C
with bacteria containing the control RNAi plasmid (L4440, blue) or the acn-1 RNAi plasmid
(red). Hermaphrodites were exposed to RNAi bacteria starting at the embryonic stage. See
Table 2 for summary statistics. These data represent a single experiment (N = 50). (C) Survival
curves of wild-type (WT) hermaphrodites cultured at 20°C with E. coli OP50 that was killed by
exposure to ultraviolet light with no drug or 2.54 mM captopril (Cap) in the NGMmedium.
Hermaphrodites were exposed to captopril starting at the L4 stage (day 0) and monitored regu-
larly until death. See Table 1 for summary statistics, number of animals and number of inde-
pendent experiments.
(TIF)
S2 Fig. Captopril did not strongly affect the age-related decline of pharyngeal pumping.
Bars show the pharyngeal pumping rate in beats per minute and the standard deviation. The
rate was measured by counting beats for 10 seconds using a dissecting microscope. Wild-type
animals were treated with no drug (blue) or 2.54 mM captopril (red) starting at the L4 stage
(day 0) and cultured at 20°C (N = 25). n.s., not significant, P> 0.05. Captopril treated animals
displayed a small increase in pumping rate at days 5–9, but this trend was not statistically sig-
nificant with this sample size.
(TIF)
S3 Fig. Captopril and acn-1 RNAi did not strongly affect self-fertile reproduction.Wild
type self-fertile hermaphrodites were cultured at 20°C and treated with (A, B) no drug (blue) or
2.54 mM captopril (red) starting at the L4 stage (day 0). (C, D) Animals were cultured with
RNAi bacteria containing the control RNAi plasmid (L4440, blue) or the acn-1 RNAi plasmid
(red). Hermaphrodites were exposed to RNAi bacteria starting at the embryonic stage. (A, C)
Bars show total number of live progeny and standard deviation. (B, D) Data points show total
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number of live progeny produced each day. Number of animals analyzed: no drug (N = 3), cap-
topril (N = 3), Control RNAi (N = 5) and acn-1 RNAi (N = 5). n.s., not significant, P> 0.05.
(TIF)
S4 Fig. Treatment with acn-1 RNAi reduced the level of acn-1mRNA.mRNA was isolated
from populations of two day old adult rrf-3(pk1426) animals cultured with control RNAi (blue)
or acn-1 RNAi (red). acn-1 transcript levels were analyzed by RT-PCR; mRNA levels are
expressed in arbitrary units (A.U.) and were normalized to rps-23, a ribosomal protein. The
values were normalized by setting the value for control RNAi equal to 1.0. Bars represent the
average +/- S.E.M. (n = 3 biological replicates).
(TIF)
S5 Fig. acn-1 RNAi extended the lifespan of age-1(am88)mutant animals. Survival curves of
age-1(am88)mutant hermaphrodites cultured at 20°C with bacteria containing the control
RNAi plasmid (L4440, blue) or the acn-1 RNAi plasmid (red). Hermaphrodites were exposed
to RNAi bacteria starting at the embryonic stage and monitored regularly until death. See
Table 2 for summary statistics, number of animals and number of independent experiments.
(TIF)
S6 Fig. acn-1 RNAi did not cause a Daf-c phenotype or nuclear localization of DAF-16::
GFP. Bars (A) and data points (B) indicate the percent of embryos that formed dauer larvae
and standard deviation. Adult hermaphrodites were cultured at 20°C with bacteria containing
the control RNAi plasmid (L4440, blue) or the acn-1 RNAi plasmid (red). Embryos were cul-
tured for three days at 27°C (A) or the indicated temperature (B) and scored for dauer larvae
formation based on morphological criteria using a dissecting microscope. (A) Genotypes were
wild type and rrf-3(pk1426). (B) daf-2 (e1370) caused a temperature sensitive Daf-c phenotype
when cultured with no RNAi (E. coli OP50 bacteria) (purple triangles). Control RNAi and acn-
1 RNAi both increased the penetrance of the Daf-c phenotype to a similar extent, indicating
that the effect is caused by the bacterial strain used for RNAi rather than the inhibition of the
acn-1 gene. Comparisons are to the paired control RNAi: n.s., not significant, P> 0.05. (C)
Representative fluorescence microscope images of hermaphrodites that contain a DAF-16::
GFP transgene. Animals were cultured with control RNAi (upper panels) or acn-1 RNAi
(lower panels). Animals were cultured at 20°C continuously (left panels) or heat shocked by
exposure to 35°C for 30 minutes (right panels). In standard culture conditions, DAF-16::GFP
was not nuclear localized (left panels). By contrast, heat shock caused nuclear localization of
DAF-16::GFP (right panels, red arrows indicate fluorescent nuclei). Animals treated with acn-1
RNAi were similar to animals treated with control RNAi.
(TIF)
S1 Table. acn-1 RNAi and Captopril treatment did not cause substantial nuclear localiza-
tion of DAF-16::GFP 1 RNAi: Animals were cultured at 20°C with bacteria containing the
control RNAi plasmid (L4440) or the acn-1 and / or daf-2 RNAi plasmid starting at the
embryonic stage. 2Drug: Animals were cultured on standard NGM (None) or with NGM con-
taining 2.5mM captopril starting at the L4 stage. 3Animals were transferred for 30 min to 35°C,
a heat stress. 4GFP was diffusely localized in the cytosol. 5GFP localization was defined as
“nuclear” if most or all nuclei displayed intensely fluorescing puncta throughout the entire
body from head to tail, or defined as “intermediate” if puncta were observed in at least one or
more nuclei but not most or all nuclei. 6N: Number of hermaphrodites analyzed.
(DOCX)
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